A Study of VET3-TGI in Patients With Solid Tumors
Recruiting now · Phase 1
Conditions studied: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
In brief
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Key facts
- Study ID
- NCT06444815
- Run by
- KaliVir Immunotherapeutics
- People needed
- 60
- Starts
- 2024-09-16
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-04-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- UC Irvine Health — Orange, California, United States (enrolling)
- University of Miami — Miami, Florida, United States (enrolling)
- Community Health Network — Indianapolis, Indiana, United States (enrolling)
- UPMC- Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
- Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.